Press Releases April 30, 2026 04:05 PM

PEDEVCO Schedules First Quarter 2026 Conference Call for May 14, 2026 at 5:00 p.m. ET

PEDEVCO schedules Q1 2026 earnings call for May 14 to discuss financial results post-merger.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
PED

PEDEVCO Corp. (NYSE American: PED), an energy company specializing in strategic oil and gas assets mainly in the Rocky Mountain and Permian Basins, announced its first quarter 2026 financial results will be released prior to a conference call on May 14, 2026. The company recently completed a merger in October 2025, significantly expanding its asset base to over 310,000 net acres across key U.S. basins. Investors and analysts will have the opportunity to engage with management during the call.

PEDEVCO Schedules First Quarter 2026 Conference Call for May 14, 2026 at 5:00 p.m. ET
PED
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • PEDEVCO operates major oil and gas assets in the D-J Basin, Powder River Basin, and Permian Basin totaling over 310,000 net acres.
  • The company completed a significant merger in October 2025 with Juniper Capital Advisors' portfolio companies, enhancing its asset portfolio.
  • Q1 2026 financial results will be discussed in a call scheduled for May 14, 2026, providing insights into post-merger performance.

HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the Rocky Mountain region, will host a conference call on Thursday, May 14, 2026, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2026. The Company’s results will be reported in a press release prior to the call.

PEDEVCO’s management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions prior to the call by emailing the Company’s investor relations team, Elevate IR, at PED@elevate-ir.com.

Date: Thursday, May 14, 2026
Time: 5:00 p.m. Eastern time
Dial-in registration link: here
Webcast registration link: here

The conference call will also be available for replay in the Events section of the Company’s website at https://www.pedevco.com/investors.

About PEDEVCO Corp.
PEDEVCO Corp. (NYSE American: PED) is a publicly traded energy company engaged in the acquisition and development of strategic oil and gas assets in the United States. Following the completion of its October 2025 merger with certain portfolio companies controlled by Juniper Capital Advisors, L.P., the Company’s principal assets include its D-J Basin assets in southeastern Wyoming and northern Colorado, its Powder River Basin assets in northeastern Wyoming, and its Permian Basin assets in eastern New Mexico, collectively representing over 310,000 net acres. PEDEVCO is headquartered in Houston, Texas. More information about PEDEVCO can be found at www.pedevco.com.

CONTACTS:
Media Contact:
PEDEVCO Corp.
(713) 221-1768
PR@pedevco.com

Investor Relations Contact:
Sean Mansouri, CFA or Laurent Weil
Elevate IR
(720) 330-2829
PED@elevate-ir.com


Risks

  • Results of the October 2025 merger and integration could present operational and financial uncertainties impacting future performance.
  • Volatility in oil and gas commodity prices could affect revenue and profitability given the company's energy sector exposure.
  • Regulatory and environmental risks inherent to oil and gas operations may influence operational costs and compliance requirements.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026